InsiderTrades.com logo
K Gary Barnette net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

K Barnette Biography and Net Worth

Insider of Veru

Gary Barnette, Ph.D. is the Chief Scientific Officer of Veru. Prior to joining Veru, Dr. Barnette was Sr. Vice President of Scientific and Regulatory Affairs at Camargo Pharmaceutical Services, LLC, during which he oversaw the development of scientific and regulatory drug development strategies across all therapeutic areas for 6 years. From 2000 to 2012, Dr. Barnette served in various positions at GTx, Inc., including as Vice President, Clinical Development Strategy. Throughout his tenure at GTx, Dr. Barnette managed responsibilities across regulatory, clinical, clinical pharmacology, and medical affairs departments for urology (men’s health) and cancer supportive care. Prior to GTx, Dr. Barnette was a Clinical Pharmacology and Biopharmaceutics Reviewer at the U.S. FDA, where he received numerous awards for reviewing, mentoring, and serving on various FDA guidance development groups and initiative task forces. Dr. Barnette holds a Ph.D. in Basic Pharmaceutical Sciences (Clinical Pharmacology and Pharmacokinetics) from West Virginia University, School of Pharmacy.

What is K Gary Barnette's net worth?

The estimated net worth of K Gary Barnette is at least $5.78 thousand as of August 13th, 2026. Barnette owns 2,300 shares of Veru stock worth more than $5,785 as of September 25th. This net worth evaluation does not reflect any other assets that Barnette may own. Learn More about K Gary Barnette's net worth.

How do I contact K Gary Barnette?

The corporate mailing address for Barnette and other Veru executives is 2916 N. Miami Avenue, Suite 1000, Miami, FL, 33127. Veru can also be reached via phone at (312) 595-9123 and via email at [email protected]. Learn More on K Gary Barnette's contact information.

Has K Gary Barnette been buying or selling shares of Veru?

Over the course of the past ninety days, K Gary Barnette has bought $4,842.00 in shares of Veru stock. Most recently, on Thursday, August 13th, K Gary Barnette bought 1,800 shares of Veru stock. The stock was acquired at an average cost of $2.69 per share, with a total value of $4,842.00. Following the completion of the transaction, the insider now directly owns 2,300 shares of the company's stock, valued at $6,187. Learn More on K Gary Barnette's trading history.

Who are Veru's active insiders?

Veru's insider roster includes K Barnette (Insider), Harry Fisch (Director), Lucy Lu (Director), and Michael Rankowitz (Director). Learn More on Veru's active insiders.

Are insiders buying or selling shares of Veru?

During the last year, Veru insiders bought shares 1 times. They purchased a total of 1,800 shares worth more than $4,842.00. The most recent insider tranaction occured on August, 13th when insider K Gary Barnette bought 1,800 shares worth more than $4,842.00. Insiders at Veru own 14.2% of the company. Learn More about insider trades at Veru.

Information on this page was last updated on 8/13/2026.

K Gary Barnette Insider Trading History at Veru

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/13/2026Buy1,800$2.69$4,842.002,300View SEC Filing Icon  
5/24/2024Buy500$13.40$6,700.00500View SEC Filing Icon  
12/16/2020Sell10,000$106.50$1,065,000.00View SEC Filing Icon  
12/18/2018Buy10,000$14.60$146,000.00View SEC Filing Icon  
See Full Table

K Gary Barnette Buying and Selling Activity at Veru

This chart shows K Gary Barnette's buying and selling at Veru by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Veru Company Overview

Veru logo
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $2.52
Low: $2.50
High: $2.57

50 Day Range

MA: $2.50
Low: $2.21
High: $2.80

2 Week Range

Now: $2.52
Low: $2.05
High: $7.33

Volume

78,823 shs

Average Volume

752,949 shs

Market Capitalization

$42.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A